EWC vs XBI
iShares MSCI Canada ETF vs SPDR S&P Biotech ETF
- • XBI has the lower expense ratio at 0.35% vs 0.50% for EWC.
- • EWC pays a higher dividend yield (1.24%).
Side-by-side metrics
| Metric | EWC | XBI |
|---|---|---|
Expense ratio Annual fee. Lower is better. | 0.50% | 0.35% |
Dividend yield Trailing 12-month yield. | 1.24% | 0.35% |
AUM Assets under management — bigger funds are typically more liquid. | $7.58B | $10.92B |
YTD return | 13.60% | 28.80% |
1-year return | — | — |
3-year return Annualized. | — | — |
5-year return Annualized. | — | — |
10-year return Annualized. | — | — |
Beta (3Y) Volatility relative to the market. Closer to 1 = market-like. | 0.73 | 1.01 |
P/E ratio | 18.91 | — |
Last price | $60.61 | $156.41 |
Inception | — | — |
Issuer | iShares | State Street |
EWC top holdings
| RY | Royal Bank of Canada | 9.11% |
| TD | The Toronto-Dominion Bank | 6.65% |
| SHOP | Shopify Inc Registered Shs -A- Subord Vtg | 6.18% |
| BMO.TO | Bank of Montreal | 3.78% |
| CNQ.TO | Canadian Natural Resources Ltd | 3.77% |
| BNS.TO | Bank of Nova Scotia | 3.71% |
| ENB.TO | Enbridge Inc | 3.49% |
| CM.TO | Canadian Imperial Bank of Commerce | 3.44% |
| SU.TO | Suncor Energy Inc | 3.04% |
| AEM.TO | Agnico Eagle Mines Ltd | 2.71% |
XBI top holdings
| MRNA | Moderna Inc | 2.37% |
| NTRA | Natera Inc | 1.82% |
| HALO | Halozyme Therapeutics Inc | 1.77% |
| TWST | Twist Bioscience Corp | 1.77% |
| BIIB | Biogen Inc | 1.75% |
| AMGN | Amgen Inc | 1.73% |
| EXEL | Exelixis Inc | 1.73% |
| UTHR | United Therapeutics Corp | 1.72% |
| ABBV | AbbVie Inc | 1.71% |
| GILD | Gilead Sciences Inc | 1.70% |
About EWC
EWC (iShares MSCI Canada ETF) is Canadian large and mid-cap equities. Managed by iShares, the fund carries $7.6B in assets under management, an expense ratio of 0.50%, a dividend yield of 1.24%. Its largest holding is Royal Bank of Canada (RY), which represents 9.1% of the portfolio. Consumer Cyclical is the fund's largest sector exposure at 3.4%.
About XBI
XBI (SPDR S&P Biotech ETF) is Equal-weight biotech stocks in the S&P Biotech Index. Managed by State Street, the fund carries $10.9B in assets under management, an expense ratio of 0.35%, a dividend yield of 0.35%. Its largest holding is Moderna Inc (MRNA), which represents 2.4% of the portfolio. Financial Services is the fund's largest sector exposure at 0.6%.